Inflation Reduction Act (IRA): Assessing the implications of Medicare drug price negotiations for drug development sponsors

Focusing on rare kidney diseases with unique collaborative efforts

Explore Fortrea's unique collaborative efforts in researching and addressing rare kidney diseases through advanced methodologies and patient-centric approaches.

SGLT2 inhibitors as renoprotective agents for pediatric patients living with chronic kidney disease

Explore the benefits of SGLT2 inhibitors as renoprotective agents for pediatric patients. Fortrea’s blog provides insights into diabetes medication and renal protection.

Delivering efficient, technology-driven patient safety solutions

This infosheet explores Fortrea's pharmacovigilance and patient safety solutions.

Serving as an extended safety partner for an emerging biotech's vaccine studies

Exceeding challenging milestones through teamwork and innovation

This case study delves into meeting and exceeding trial milestones on very short timelines.

Elevate your neuromuscular clinical studies with Fortrea’s specialized expertise and comprehensive support

Sharing our best patient-centric practices from extensive experience in Alzheimer’s Disease.

At Fortrea, we’re committed to advancing research in Alzheimer’s Disease (AD) and other dementias. Learn about our best practices and recommendations developed from years of experience advancing these complex studies.

Going beyond the boundaries of a clinical trial: how Dr. Barbara Gillespie is working to address disparities in kidney disease

As part of her commitment to advancing nephrology research, Dr. Gillespie is helping build trust in clinical trials within patient groups. H